Advanced Biotherapy Inc. Reports Clinical Results in Multiple Sclerosis Patients; Study Supports the Company's Treatment Strategy.Business Editors & Health/Medical Writers WOODLAND HILLS, Calif.--(BUSINESS WIRE)--Sept. 6, 2000 Advanced Biotherapy, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :ADVB ADVB Associação dos Dirigentes de Vendas e Marketing do Brasil ), announced today the results of a 60 patient randomized ran·dom·ize tr.v. ran·dom·ized, ran·dom·iz·ing, ran·dom·iz·es To make random in arrangement, especially in order to control the variables in an experiment. , double blind, placebo controlled clinical trial controlled clinical trial, n a research strategy that calls for two samples: an experimental sample of patients receiving a pharmaceutical, and a second sample of control patients receiving a placebo. evaluating the efficacy of its proprietary Anti-interferon-gamma drug (Anti-IFNg), for the treatment of Secondary Progressive Multiple Sclerosis (MS) patients. The results showed statistically significant improvements, at both six and 12 months after treatment, when compared to both the placebo group and the group treated with Anti-Tumor necrosis factor-alpha (Anti-TNFa). The trial was conducted at the Russian State Medical University, in Moscow, Russia. Drug treatments were administered twice daily for five days and an extensive battery of clinical indices of disease progression were evaluated for a period of one year post-treatment. The parameters evaluated included Functional and Disability scores, Magnetic Resonance Imaging magnetic resonance imaging (MRI), noninvasive diagnostic technique that uses nuclear magnetic resonance to produce cross-sectional images of organs and other internal body structures. (MRI 1. (application) MRI - Magnetic Resonance Imaging. 2. MRI - Measurement Requirements and Interface. ), Evoked Potentials and various biochemical indices. The 15 patients in the Anti-IFNg group, had statistically significantly better outcomes at both six and 12 months treatment when compared to either the 15 patients receiving a Placebo, 15 patients receiving Anti-TNFa, or the 15 patients treated with both antibodies. Commenting on the results, Dr. Paul J. Marangos, Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Advanced Biotherapy, Inc. stated, "We are very pleased about the results of this study demonstrating the superiority of our proprietary Anti-IFNg approach for treating MS patients when compared to Anti-TNFa." He added, "This study positions us favorably for the continued development of this product." Advanced Biotherapy, Inc. is developing proprietary treatments for a range of autoimmune diseases, including Rheumatoid Arthritis, Multiple Sclerosis, Type I Diabetes Type I diabetes Also called juvenile diabetes. Type I diabetes typically begins early in life. Affected individuals have a primary insulin deficiency and must take insulin injections. Mentioned in: Diabetic Ketoacidosis and AIDS. The company's drugs neutralize immunomodulators called Cytokines, which have now been shown to be linked to these diseases. Statements made in this release, other than statements of historical fact, are forward-looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the results of clinical trials, the progress of research and product development programs, the regulatory approval process, competitive products, future capital requirements and the extent and breadth of the company's patent portfolio. See the company's public filings with the Securities and Exchange Commission for information about risks that may affect the company. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion